Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
NEW YORK–(BUSINESS WIRE)–Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are... Read more.
Teoayeah’s Christmas Gift List for All Kids (12/11-12/24)
HOUSTON–(BUSINESS WIRE)–The annual Christmas season is just around the corner and the festive spirit fills the air. In order to give every child a satisfying... Read more.
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients.... Read more.
Belgian, Port Houston and Partners Sign Memorandum of Understanding on Energy Transition Cooperation
HOUSTON–(BUSINESS WIRE)–Today, H.E. Alexander De Croo, Prime Minister of Belgium, witnessed the signing of a Memorandum of Understanding on Energy Transition... Read more.
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia A and B without inhibitors,... Read more.
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting
– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen... Read more.
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® (luspatercept-aamt)... Read more.
LPSN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of LivePerson, Inc. (NASDAQ: LPSN) securities between... Read more.
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH... Read more.
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
— FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women — — Study Designed to Provide... Read more.